Additional file 3 of Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma

Additional file 3: Table S3. Clinical and molecular data of TCGA-PTC tumors in I and IV TIMP3 quartiles. Fisher's exact test measuring the association between TIMP3 expression levels and the occurrence of BRAFV600E mutation and patient characteristics in PTC cases of TCGA cohort for which molecular and clinical information were available. Benjamini–Hochberg procedure (BH) was applied for multiple test correction (adj_p-value). Samples are stratified in I and IV quartiles according to TIMP3 expression levels.

补充材料3：表S3。处于金属蛋白酶组织抑制剂3（TIMP3）表达量I、IV四分位组的TCGA-PTC肿瘤样本的临床及分子数据。针对癌症基因组图谱（The Cancer Genome Atlas, TCGA）队列中具备完整分子与临床信息的甲状腺乳头状癌（Papillary Thyroid Carcinoma, PTC）病例，采用Fisher精确检验分析TIMP3表达水平与BRAFV600E突变发生情况及患者临床特征之间的关联。本研究采用Benjamini-Hochberg（BH）校正法进行多重检验校正，校正后P值记为adj_p-value。所有样本依据TIMP3表达水平被划分为I、IV两个四分位组。